Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m 2 IV) and cyclophosphamide (600 mg/m 2 IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.
|Number of pages||3|
|Journal||European Journal of Gynaecological Oncology|
|Publication status||Published - 1990|
ASJC Scopus subject areas
- Obstetrics and Gynaecology